Introduction
Fibroblast growth factor 21 (FGF21) is a circulating metabolic hormone predominantly secreted from the liver and from other tissues, such as adipose tissue, pancreas and skeletal muscle (1; 2) . Numerous animal studies have demonstrated its favorable effects on insulin sensitivity, glucose and lipid metabolism, and body weight, in obese mice and diabetic monkeys (1) (2) (3) (4) (5) . High circulating levels of FGF21, however, have been observed in patients with obesity and a range of obesity-related conditions, including type 2 diabetes (T2DM), coronary artery disease (CAD) and the metabolic syndrome (MetS) (1) . Our group previously showed that elevated levels of FGF21 independently predicted the development of T2DM (6) , carotid atherosclerosis (7), and kidney disease progression in T2DM subjects (8) .
Observations of the paradoxical increase of FGF21 in the above diseases may represent a compensatory response to FGF21 resistance, which has been demonstrated in a previous study of mice with diet-induced obesity (9), or to combat the metabolic disturbances in these disease conditions.
The circulating levels of FGF21 have been reported to be moderately heritable in a twin study of young adults, with 40% of variation attributed to genetic determinants (10) . So far, only a few genetic variants have been reported to show weak associations with circulating FGF21 levels (11; 12) . No previous genome-wide or exome-wide association analyses on circulating FGF21 levels have been published to date. The heritability of circulating FGF21 levels remains largely unexplained. This study sought to identify the genetic determinants of circulating FGF21 levels. We conducted an exome-chip association analysis on circulating FGF21 levels using a specially designed Illumina HumanExome
BeadChip (Asian Exome-chip) in a Chinese population (13; 14) . In consideration of the possible difference in circulating FGF21 levels between individuals from the patient groups and those from the general population, possibly due to the intrinsic metabolic stress under disease conditions and the treatment effects on FGF21 expression, we first conducted the association analysis in a community-based and two clinic-based cohorts separately, followed by a combined analysis involving a total of 5169 individuals.
Research Design and Methods

Subjects
An exome-chip association study on circulating FGF21 levels was performed in 5169
Chinese individuals who were recruited from the Hong Kong Cardiovascular Risk Factor
Prevalence Study (CRISPS; n=1172); the Hong Kong West Diabetes Registry (HKWDR; n=2884); and the Hong Kong Chinese Coronary Artery Disease (HK-CAD) study (n=1113).
Details of the study cohorts and measurement of FGF21 levels were described in the Supplementary notes.
Genotyping and data quality control
All subjects were genotyped using the custom Asian Exome-chip (13; 14) with an add-on content of 58,317 single nucleotide polymorphisms (SNPs), including a custom panel of over 30,000 missense or nonsense coding variants on top of the standard content of the Infinium HumanExome BeadChip (HumanExome-12v1_A; Illumina, CA). Genotyping of the Exome array was performed using the Illumina iScan system platform at the Centre for Genomic
Sciences of the University of Hong Kong. The GenTrain version 2.0 in GenomeStudio V2011.1 (Illumina) was used to perform genotyping calling. Details of genotype quality control were described in the Supplementary notes. After all QC measures, a total of 1172 subjects and 76,389 variants remained in the association analysis of the CRISPS cohort, 6 whilst the analyses of the clinic-based cohorts included a total of 2884 subjects and 77598
variants from the HKWDR; and 1113 subjects and 75468 variants from the HK-CAD study.
The combined analysis included only polymorphic SNPs in all three cohorts and had MAF ≥0.1%, totaling 5169 subjects and 70,444 variants. The P-value informed linkage disequilibrium (LD) based clumping approach with the "--clump" command implemented in PLINK was performed to address the between-SNP LD. Each index SNP represented the strongest association P-value from each clumped region. Each index SNP formed clumps with other variants which were within ± 500kb from the index SNP and in LD with the index SNP (r 2 ≥0.2).
Statistical analysis
For each cohort, we carried out single-variant association tests, under the additive genetic model, for all markers that passed quality controls using PLINK version 1.9 (15) . The FGF21 levels were first transformed to rank-based inverse normal residuals before analysis to ensure normality and minimize the possible effect of outliers. Age, sex and the first 2 principal components (PCs) were included as covariates in the multiple linear regression model (Model 1) (Supplementary Figure 1) . To assess adiposity independent association, body mass index 
Results
Exome-chip association study for circulating FGF21 levels
Of the 70,444 polymorphic SNPs ( Figure 2 ) examined for associations with circulating FGF21 levels in 5169 Chinese individuals (Table 1) , 45.06% altered protein composition and 19.96% were Asian-specific variants with MAF 0.1-5%.
The strongest association was detected at a missense variant rs1260326 (p.Pro446Leu) of GCKR ( Table 2 and Supplementary Figure 2 ). The T (Leu446) allele of rs1260326 was significantly associated with a higher level of FGF21 levels at genome-wide significance ( P heterogeneity =0.590; I 2 =0) with FGF21 levels in adjustment Model 1. The associations of these two variants were slightly attenuated on further adjustment for BMI (Table 2 ).
Supplementary table 1 shows the 27 index SNPs which showed associations with FGF21
level at P combined <5x10 -4 in the combined analysis.
Discussion
The current study reports the first exome-chip association analysis on circulating FGF21 levels. By genotyping 5169 Chinese individuals using a custom Asian Exome-chip, we identified a genome-wide significant association between GCKR rs1260326, a proline to leucine substitution at amino acid 446 (p.Pro446Leu), and circulating FGF21 levels. Our study has shed light on the possible role of GCKR on the regulation of circulating FGF21 levels. GCKR, encoding the glucokinase regulator (also known as glucokinase regulatory protein [GKRP]), has been implicated in a wide range of important metabolic pathways, such as glucose homeostasis and lipid metabolism (18) . Both FGF21 and GCKR are highly expressed in the liver (1; 18). GCKR acts as a competitive inhibitor of glucokinase (GCK), the principal modulator of glucose uptake and release in the liver (18) . GCKR forms an inhibitory complex with GCK (GCKR-GCK complex), and allosterically controls its activity in the presence of fructose. Dissociation of the GCKR-GCK complex facilitates the translocation of GCK to cytoplasm where hepatic glycolysis is stimulated (18) .
The Pro446 residue of GCKR is conserved across various species, including human and rat.
GCKR p.Pro446Leu is located in close proximity to Asp413 and Gln443 which form a critical salt bridge with Arg186 of GCK (19) . Thus, the variant could interfere directly with the binding of GCKR to GCK (19) , thereby leading to reduced inhibition of GCK. This in turn contributed to an enhanced glycolytic flux and promoted uptake of glucose into the liver.
Accompanying this increased rate of glycolysis is the raised levels of other liver metabolites, such as malonyl-CoA which ultimately lead to enhanced production of TG (20) . This explains the reduced FPG and raised TG levels observed in individuals carrying the Leu446 treatment has demonstrated a rapid and prominent reduction in circulating TG, which occurred as soon as two days after treatment (24) . However, there was lack of significant effect on glycemic control in humans (24; 25), contradictory to the glucose lowering effect of FGF21 observed in animals (4; 5). In line with these reports, the GCKR rs1260326 was found to be strongly associated with TG but only modestly correlated with FPG in the current study (24; 25) . Taken together, these findings suggest that FGF21 may play a more prominent role in regulating lipid metabolism and adiposity, rather than blood glucose. On the other hand, our finding that rs1260326 could possibly influence the circulating levels of FGF21 via enhanced GCK activity, also suggest that alterations in hepatic carbohydrate metabolism can impact on FGF21 expression and its circulating levels.
The major limitation of the current study was the lack of external validations. Further replication analysis in independent cohorts in other Asians or European populations would serve to validate our findings. The design of the exome-chip has allowed us to examine more coding variants with much lower MAF compared to conventional genome-wide association studies. However, the relatively small sample size has limited our study power to detect the association of rare or low-frequency variants. With a view to achieve a larger sample size, a meta-analysis of genome/exome-wide association studies would be useful to identify additional genetic variants influencing FGF21 levels.
In summary, we conducted an exome-chip association analysis and identified, for the first time, a highly significant association of a functional variant of GCKR, rs1260326
(p.Pro446Leu), with circulating FGF21 levels, independent of obesity and other metabolic 
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Supplementary notes
Subjects
All subjects of the current study were previously examined in the exome-array association studies of T2DM (1), blood lipid traits and CAD (2) . Only those subjects who also had their blood samples available for measurement of circulating FGF21 levels were included in the present study. All participants gave written informed consent and the study protocol was 
Measurement of circulating FGF21 levels
Blood FGF21 levels of subjects were measured using a human FGF21 enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's protocol (Antibody and
Immunoassay Services, University of Hong Kong) as previously described (6) . Samples were diluted 1:1 before the assay was conducted. The 100ul diluted samples, calibrators, and quality controls were added to the 96-well microtiter plates coated with an affinity-purified polyclonal anti-human FGF21 antibody. A calibration curve was constructed by plotting the absorbance values at 450nm against FGF21 concentrations of the calibrators. The FGF21 concentrations in the study samples were then determined by using the calibration curve. The intra-and inter-assay coefficients of variation of the FGF21 ELISA were 4 to 5% and 3.5 to 10.2%, respectively.
Quality control of genotype data
Manual curation of genotype calls was conducted for over 55,000 variants which had a 
